Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Januar 2025 08:00 ET | Quelle: Kailera Therapeutics, Inc.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531

Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.
08. Januar 2025 08:05 ET | Quelle: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Kailera Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.
06. Januar 2025 08:15 ET | Quelle: Kailera Therapeutics, Inc.

Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
12. November 2024 08:00 ET | Quelle: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer

Today, Kailera Therapeutics announced the appointment of Scott Akamine as Chief Legal Officer.
01. Oktober 2024 07:00 ET | Quelle: Kailera Therapeutics, Inc.

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions

Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.

Vorherige Seite